Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID A HINCHMAN

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1710914528
CMS profile
122524
Location
BOISE, ID

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$181.14

11 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $169.16 10
Education $11.98 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Amgen Inc. $40.38 2
Novartis Pharmaceuticals Corporation $33.84 2
Medtronic USA, Inc. $28.18 1
PORTOLA PHARMACEUTICALS, INC. $24.11 2
E.R. Squibb & Sons, L.L.C. $23.90 2
PFIZER INC. $18.75 1
Chiesi USA, Inc. $11.98 1

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID A HINCHMAN

NPI 1710914528 · CMS profile ID 122524

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

BOISE, ID

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1710914528?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID A HINCHMAN, NPI 1710914528, CMS profile ID 122524. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1710914528?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). DAVID A HINCHMAN, NPI 1710914528, CMS profile ID 122524. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1710914528?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
DAVID A HINCHMAN, NPI 1710914528, CMS profile ID 122524, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1710914528?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

11 matching records · $181.14 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 11 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–11 of 11.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $12.8012/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651223793 CMS
Novartis Pharmaceuticals Corporation $17.8811/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659583981 CMS
PFIZER INC. $18.7508/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672582837 CMS
E.R. Squibb & Sons, L.L.C. $11.1007/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651223759 CMS
PORTOLA PHARMACEUTICALS, INC. $13.0005/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705262259 CMS
Amgen Inc. $15.3705/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662278325 CMS
Chiesi USA, Inc. $11.9804/26/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703584809 CMS
Medtronic USA, Inc. $28.1804/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 667605973 CMS
PORTOLA PHARMACEUTICALS, INC. $11.1104/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705258027 CMS
Novartis Pharmaceuticals Corporation $15.9604/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659583979 CMS
Amgen Inc. $25.0102/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662278323 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $181.14 11
PY2021 $168.75 5
PY2022 $11,464.89 18
PY2023 $71,624.38 127
PY2024 $88,566.54 158
PY2025 $152,409.43 151

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,669.33 1
PY2025 Principal investigator $312,600.42 16
PY2024 Recipient $70,959.20 2
PY2024 Principal investigator $52,849.00 4
PY2023 Principal investigator $65,514.00 33
PY2022 Recipient $13,862.00 1
PY2022 Principal investigator $212,977.69 60
PY2021 Principal investigator $197,207.64 41
PY2020 Principal investigator $175,269.34 38
PY2019 Principal investigator $288,116.48 44

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

61 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ARRAY BIOPHARMA INC $1,200.00 12/20/2022 Covered Recipient Teaching Hospital
ST. LUKES REGIONAL MEDICAL CENTER
A PHASE 3 MULTINATIONAL RANDOMIZED PLACEBOCONTROLLED STUDY OF ARRY371797 PF07265803 IN PATIENTS WITH SYMPTOMATIC DILATED CARDIOMYOPATHY DUE TO A LAMIN AC GENE MUTATION No dispute reported 06/30/2026 949772325
Principal investigator 1 ARRAY BIOPHARMA INC $800.00 12/20/2022 Covered Recipient Teaching Hospital
ST. LUKES REGIONAL MEDICAL CENTER
A PHASE 3 MULTINATIONAL RANDOMIZED PLACEBOCONTROLLED STUDY OF ARRY371797 PF07265803 IN PATIENTS WITH SYMPTOMATIC DILATED CARDIOMYOPATHY DUE TO A LAMIN AC GENE MUTATION No dispute reported 06/30/2026 949772469
Principal investigator 1 CSL Behring $50.00 12/16/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 940350057
Principal investigator 1 CSL Behring $1,297.66 12/16/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 940350059
Principal investigator 1 CSL Behring $250.00 12/09/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 940350055
Principal investigator 1 BOSTON SCIENTIFIC CORPORATION $3,219.85 11/21/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
LUX TRENDS No dispute reported 06/30/2026 918814581
Principal investigator 1 ARRAY BIOPHARMA INC $500.00 11/08/2022 Covered Recipient Teaching Hospital
ST. LUKES REGIONAL MEDICAL CENTER
A PHASE 3 MULTINATIONAL RANDOMIZED PLACEBOCONTROLLED STUDY OF ARRY371797 PF07265803 IN PATIENTS WITH SYMPTOMATIC DILATED CARDIOMYOPATHY DUE TO A LAMIN AC GENE MUTATION No dispute reported 06/30/2026 949772327
Principal investigator 1 American Regent $10,984.00 10/17/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
Heart_FID No dispute reported 06/30/2026 923497339
Principal investigator 1 CSL Behring $100.00 10/10/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 940350035
Principal investigator 1 CSL Behring $1,666.08 10/10/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 940350037
Principal investigator 1 CSL Behring $2.10 09/27/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 940350019
Principal investigator 1 CSL Behring $45.20 09/27/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 940350021
Principal investigator 1 CSL Behring $123.60 09/27/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 940350023
Principal investigator 1 CSL Behring $2,555.46 09/23/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 940349969
Principal investigator 1 CSL Behring $100.00 09/23/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 940349971
Recipient Eli Lilly and Company $13,862.00 09/20/2022 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION AND OBESITY (SUMMIT No dispute reported 06/30/2026 917813153
Principal investigator 1 BOSTON SCIENTIFIC CORPORATION $272.84 09/01/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
LUX TRENDS No dispute reported 06/30/2026 918819667
Principal investigator 1 CSL Behring $1,403.10 08/26/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 940349961
Principal investigator 1 CSL Behring $50.00 08/26/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 940349963
Principal investigator 1 ARRAY BIOPHARMA INC $1,000.00 08/11/2022 Covered Recipient Teaching Hospital
ST. LUKES REGIONAL MEDICAL CENTER
A PHASE 3 MULTINATIONAL RANDOMIZED PLACEBOCONTROLLED STUDY OF ARRY371797 PF07265803 IN PATIENTS WITH SYMPTOMATIC DILATED CARDIOMYOPATHY DUE TO A LAMIN AC GENE MUTATION No dispute reported 06/30/2026 949797459
Principal investigator 1 BOSTON SCIENTIFIC CORPORATION $325.00 08/11/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
LUX TRENDS No dispute reported 06/30/2026 918819669
Principal investigator 1 American Regent $614.00 08/03/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
Heart_FID No dispute reported 06/30/2026 923497005
Principal investigator 1 CSL Behring $164.80 07/26/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 940350015
Principal investigator 1 CSL Behring $10.20 07/26/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 940350017
Principal investigator 1 CSL Behring $82.40 06/29/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 940350007
Principal investigator 1 Eli Lilly and Company $2.00 06/28/2022 Covered Recipient Teaching Hospital
ST. LUKES REGIONAL MEDICAL CENTER
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION AND OBESITY (SUMMIT No dispute reported 06/30/2026 917812513
Principal investigator 1 BOSTON SCIENTIFIC CORPORATION $1,840.00 06/17/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
LUX TRENDS No dispute reported 06/30/2026 918819345
Principal investigator 1 BOSTON SCIENTIFIC CORPORATION $517.00 06/17/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
LUX TRENDS No dispute reported 06/30/2026 918819347
Principal investigator 1 BOSTON SCIENTIFIC CORPORATION $407.00 06/17/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
LUX TRENDS No dispute reported 06/30/2026 918819349
Principal investigator 1 BOSTON SCIENTIFIC CORPORATION $245.00 06/17/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
LUX TRENDS No dispute reported 06/30/2026 918819351
Principal investigator 1 BOSTON SCIENTIFIC CORPORATION $62.00 06/17/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
LUX TRENDS No dispute reported 06/30/2026 918819353
Principal investigator 1 CSL Behring $100.00 06/08/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 940349939
Principal investigator 1 CSL Behring $4,985.10 06/08/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 940349941
Principal investigator 1 CSL Behring $1,000.00 06/03/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 940349933
Principal investigator 1 CSL Behring $1,000.00 06/03/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 940349975
Principal investigator 1 CSL Behring $50.00 05/18/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 940349925
Principal investigator 1 BOSTON SCIENTIFIC CORPORATION $4,000.00 05/16/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
LUX TRENDS No dispute reported 06/30/2026 918814091
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,812.00 05/13/2022 Non-covered Recipient Entity
SPECTRUM CLINICAL RESEARCH INC.
Dapagliflozin in Acute Decompensated Heart Failure No dispute reported 06/30/2026 914598259
Principal investigator 1 American Regent $500.00 05/11/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
Heart_FID No dispute reported 06/30/2026 923496853
Principal investigator 1 BOSTON SCIENTIFIC CORPORATION $164.99 05/02/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
LUX TRENDS No dispute reported 06/30/2026 918819355
Principal investigator 1 CSL Behring $450.00 04/27/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 940349913
Principal investigator 1 CSL Behring $10,347.30 04/27/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 940349915
Principal investigator 1 CSL Behring $1,000.00 04/22/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 940349911
Principal investigator 1 American Regent $11,427.00 04/20/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
Heart_FID No dispute reported 06/30/2026 923496665
Principal investigator 1 CSL Behring $50.00 04/15/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 940349909
Principal investigator 1 CSL Behring $15.30 03/28/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 940349995
Principal investigator 1 CSL Behring $123.60 03/28/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 940349997
Principal investigator 1 CSL Behring $100.00 03/18/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 940349897
Principal investigator 1 CSL Behring $2,366.10 03/18/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 940349899
Principal investigator 1 CSL Behring $4.20 02/23/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 940349989
Principal investigator 1 CSL Behring $12.75 02/23/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 940349991
Principal investigator 1 CSL Behring $535.60 02/23/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 940349993
Principal investigator 1 CSL Behring $50.00 02/14/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 940349891
Principal investigator 1 CSL Behring $693.90 02/14/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 940349893
Principal investigator 1 Novartis Pharmaceuticals Corporation $108,004.16 02/02/2022 Covered Recipient Teaching Hospital
ST. LUKES REGIONAL MEDICAL CENTER
PROSPECTIVE COMPARISON OF ARNI WITH ARB GIVEN FOLLOWING STABILIZATION IN DECOMPENSATED HFPEF (PARAGLIDE-HFPEF) No dispute reported 06/30/2026 909382221
Principal investigator 1 AstraZeneca Pharmaceuticals LP $22,400.00 01/28/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
Dapagliflozin in Acute Decompensated Heart Failure No dispute reported 06/30/2026 914593109
Principal investigator 1 American Regent $921.00 01/24/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
Heart_FID No dispute reported 06/30/2026 923497759
Principal investigator 1 Amgen Inc. $1,600.00 01/22/2022 Covered Recipient Teaching Hospital
ST. LUKES REGIONAL MEDICAL CENTER
20130295-FOURIER OLE (Ph 4) No dispute reported 06/30/2026 942838555
Principal investigator 1 Janssen Research & Development, LLC $350.00 01/10/2022 Non-covered Recipient Entity
St Lukes Regl Medcl Ctr
A Study on Impact of Canagliflozin on Health Status Quality of Life and Functional Status in Heart Failure No dispute reported 06/30/2026 885224063
Principal investigator 1 CSL Behring $250.00 01/07/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 940349883
Principal investigator 1 CSL Behring $4,775.40 01/07/2022 Covered Recipient Teaching Hospital
St. Lukes Regional Medical Center
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome No dispute reported 06/30/2026 940349885